Tamer Elbayoumi M.S., Ph.D.

Associate Professor & Co-Director, Nanomedicine Center of Excellence in Translational Cancer Research (Nanomedicine COE-TCR)


Midwestern University 
College of Pharmacy-Glendale
Pharmaceutical Sciences Dpt.
Glendale Hall, RM#237-17
19555 N. 59th Ave.
Glendale, AZ 85382
Office: (623) 572-3592
e-mail: telbay@midwestern.edu

EDUCATION

Ph.D. Pharmaceutical Sciences Northeastern University, Boston, MA 2006
M.S. Biomedical Sciences Northeastern University, Boston, MA 2003

RESEARCH SUMMARY

Pharmaceutical development and evaliuation of targeted nano-scale lipid-based delivery systems of therapeutics and imaging agents, at the pre-clinical and translational stages. Our current target organs/tissues include various solid tumors, skin and hematological cancers, as well as ischemic cardiac tissues, to provide enhanced antineoplastic efficacy, and protection against different pathological damages, respectively.

Selected Publications

  1. Shen R, Kim JJ, Yao M, Elbayoumi TA. Development and evaluation of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceutical. Int J Nanomedicine. 2016 Apr 26;11:1687-700. doi: 10.2147/IJN.S103332. eCollection 2016. PubMed [citation] PMID: 27217747
  2. Pham J, Nayel A, Hoang C, Elbayoumi TA. Enhanced effectiveness of tocotrienol-based nano-emulsified system for topical delivery against skin carcinomas. Drug Deliv. 2016 Jun;23(5):1514-24. doi: 10.3109/10717544.2014.966925. PubMed [citation] PMID: 25293973
  3. Elbayoumi TA. Editorial: Lipidic Nano-carrier Delivery of "Big" Molecules. Curr Pharm Biotechnol. 2016;17(8):661. PubMed [citation] PMID: 27215370
  4. Brownlow B, Nagaraj VJ, Nayel A, Joshi M, Elbayoumi TA. Development and In Vitro Evaluation of Vitamin E-Enriched Nanoemulsion Vehicles Loaded with Genistein for Chemoprevention Against UVB-Induced Skin Damage. J Pharm Sci. 2015 Oct;104(10):3510-23. doi: 10.1002/jps.24547. PubMed [citation] PMID: 26108889  
  5. Gavin A, Pham JT, Wang D, Brownlow B, Elbayoumi TA. Layered nanoemulsions as mucoadhesive buccal systems for controlled delivery of oral cancer therapeutics. Int J Nanomedicine. 2015;10:1569-84. doi: 10.2147/IJN.S75474. PubMed [citation]PMID: 25759580, PMCID: PMC4346361 
  6. Pham JT, Grundmann O, Elbayoumi TA. Mitochondriotropic nanoemulsified genistein-loaded vehicles for cancer therapy. Methods Mol Biol. 2015;1265:85-101.doi: 10.1007/978-1-4939-2288-8_7. PubMed [citation] PMID: 25634269 
  7. Phan V, Walters J, Brownlow B, Elbayoumi TA. Enhanced cytotoxicity of optimized liposomal genistein via specific induction of apoptosis in breast, ovarian and prostate carcinomas. J Drug Target. 2013 Dec;21(10):1001-11. doi:10.3109/1061186X.2013.847099. Epub 2013 Oct 24. PubMed [citation] PMID: 24151835 
  8. Pham JT, Brownlow B, Elbayoumi TA. Mitochondria-specific pro-apoptotic activity of genistein lipidic nanocarriers. Mol Pharm. 2013 Oct 7;10(10):3789-800. doi:10.1021/mp4004892. Epub 2013 Sep 18. PubMed [citation] PMID: 23992356
  9. De Rosa G, Caraglia M, Salmaso S, Elbayoumi TA. Nanotechnologies in cancer. J Drug Deliv. 2013;2013:604293. doi: 10.1155/2013/604293. Epub 2013 May 13. PubMed [citation] PMID: 23738075, PMCID: PMC3666271 
  10. Faulk A, Weissig V, Elbayoumi TA. Mitochondria-specific nano-emulsified therapy for myocardial protection against doxorubicin-induced cardiotoxicity. Methods Mol Biol. 2013;991:99-112. doi: 10.1007/978-1-62703-336-7_11. PubMed [citation] PMID:23546663 
  11. Jordan M, Elbayoumi TA, Phosophorylcholine-based Biomimetic Coatings for Nanomedical Applications. Journal of Membrane Science & Technology. 2012 December 17; 3(1):1-2 [citation]
  12. Jordan M, Nayel A, Brownlow B, Elbayoumi TA. Development and evaluation of tocopherol-rich argan oil-based nanoemulsions as vehicles possessing anticancer activity. J Biomed Nanotechnol. 2012 Dec;8(6):944-56. PubMed [citation] PMID:23030003 
  13. Elbayoumi TA. Nano drug-delivery systems in cancer therapy: gains, pitfalls and considerations in DMPK and PD. Ther Deliv. 2010 Aug;1(2):215-9. PubMed [citation] PMID: 22816128 
  14. Elbayoumi TA, Torchilin VP. Current trends in liposome research. Methods Mol Biol. 2010;605:1-27. doi: 10.1007/978-1-60327-360-2_1. PubMed [citation] PMID:20072870 
  15. Elbayoumi TA, Weissig V. Implications of intracellular distribution of nanovesicles for bioimaging studies. J Biomed Nanotechnol. 2009 Dec;5(6):620-33. Review. PubMed [citation] PMID: 20201224 
  16. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009 Mar 15;15(6):1973-80. doi: 10.1158/1078-0432.CCR-08-2392. Epub 2009 Mar 10. PubMed [citation] PMID:19276264, PMCID: PMC2762655 
  17. Elbayoumi TA, Torchilin VP. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol Pharm. 2009 Jan-Feb;6(1):246-54. doi:10.1021/mp8001528. PubMed [citation] PMID: 19049322, PMCID: PMC2651224 
  18. Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv. 2008 Nov;5(11):1185-98. doi:10.1517/17425240802497457 . Review. PubMed [citation] PMID: 18976130 
  19. Elbayoumi TA, Torchilin VP. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int J Pharm. 2008 Jun 5;357(1-2):272-9. doi: 10.1016/j.ijpharm.2008.01.041. Epub 2008 Feb 2. PubMed [citation] PMID: 18329201, PMCID: PMC2680692 
  20. Elbayoumi TA, Torchilin VP., Tumor-targeted immuno-liposomes for Cancer therapy and imaging  Journal of Pharmaceutical Innovations. 2008 March 12; 3(1):51-58 [citation]
  21. Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci. 2007 Nov;32(3):159-68. Epub 2007 Jun 7. PubMed [citation] PMID: 17707615, PMCID: PMC2151083 
  22. Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res. 2007;17(1):1-14. PubMed [citation] PMID:17454399 
  23. Elbayoumi TA, Torchilin VP. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205. Epub 2006 Jun 9. PubMed [citation] PMID: 16763815 
  24. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm. 2005 Dec 8;306(1-2):142-9. Epub 2005 Oct 19. PubMed [citation] PMID:16242875, PMCID: PMC1828137 
  25. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes:doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004 Nov 5;100(1):135-44. PubMed [citation] PMID: 15491817